ECSS
INDV icon

Eurizon Capital SGR SpA’s Indivior Pharmaceuticals INDV Stock Holding History

Eurizon Capital SGR SpA’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Hold
2,783
– – ﹤0.01% 882
2026
Q1 		$80.5K Buy
+2,783
New +$91.9K ﹤0.01% 938

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Eurizon Capital SGR SpA's INDV Position: Q2 2026 in Review

Eurizon Capital SGR SpA held its Indivior Pharmaceuticals (INDV) position steady in Q2 2026 at 2,783 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #882.

Eurizon Capital SGR SpA first reported a position in INDV in Q1 2026 and has held it in 2 quarters since. 336 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Eurizon Capital SGR SpA held 2,783 shares of Indivior Pharmaceuticals worth $115K as of Q2 2026.
  • Eurizon Capital SGR SpA left its Indivior Pharmaceuticals share count unchanged in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Eurizon Capital SGR SpA's portfolio in Q2 2026, its #882 holding.
  • Eurizon Capital SGR SpA first reported a position in Indivior Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 336 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Eurizon Capital SGR SpA's 13F filing for Q2 2026, filed 29 Jul 2026.